Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 494 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Atezolizumab Approved for Some Patients with Triple-Negative Breast Cancer March 28, 2019 ‘Inside Edition’ Anchor Thanks Viewer For Pointing Out Lump That Turned... April 24, 2019 Initial Results of the CanScreen5, an Authentic Data Repository for Cancer... May 4, 2023 Expectant Mom with “Blocked Milk Duct” Discovers She Has Cancer at... April 27, 2021 Load more HOT NEWS Helping Dogs—and Humans—with Cancer: NCI’s Comparative Oncology Studies Reducing the Cancer Burden: Future Directions for NCI’s Cancer Control Research Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer Lung Cancer Trial of Osimertinib Draws Praise—and Some Criticism
